Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethionine is a synthetic *non-proteinogenic amino acid* and a structural analog of the essential amino acid methionine, in which the methyl group is replaced with an ethyl group. It acts as an antimetabolite and inhibits normal methylation reactions in cells, interfering with biological methylation pathways, including DNA methylation. Ethionine is toxic in animals and acts as a carcinogenic agent in some experimental models. Its mechanism includes inhibition of protein synthesis and interference with methyl group transfer, and it has been extensively used in experimental research to induce liver injury, pancreatic toxicity, and liver cancer in animal models. Ethionine is not used therapeutically in humans and has no approved clinical applications[2][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethionine.